# SPS Commerce Inc: financial statements, quarterly

SPSC · Nasdaq · CIK 1092699 · [Technology](/sectors/technology.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/spsc.md) · [Financials](/companies/spsc/financials.md) · [Filings](/companies/spsc/filings.md) · [Insiders](/companies/spsc/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/spsc/financials.md?period=annual).

## Income statement

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [145 d](/filings/0001092699-26-000012.md) | [150](/filings/0001092699-25-000038.md) | [154](/filings/0001092699-25-000049.md) | [164](/filings/0001092699-25-000064.md) | [171 d](/filings/0001092699-26-000012.md) | [182](/filings/0001092699-26-000043.md) | [187](/filings/0001092699-26-000066.md) | [190](/filings/0001092699-26-000075.md) | [193 d](/filings/0001092699-26-000012.md) | [192](/filings/0001092699-26-000043.md) | [198](/filings/0001092699-26-000066.md) | [198](/filings/0001092699-26-000075.md) |
| Cost of revenue | $m | [49.0 d](/filings/0001092699-26-000012.md) | [51.5](/filings/0001092699-25-000038.md) | [52.0](/filings/0001092699-25-000049.md) | [51.6](/filings/0001092699-25-000064.md) | [55.6 d](/filings/0001092699-26-000012.md) | [56.9](/filings/0001092699-26-000043.md) | [59.8](/filings/0001092699-26-000066.md) | [57.9](/filings/0001092699-26-000075.md) | [57.0 d](/filings/0001092699-26-000012.md) | [59.2](/filings/0001092699-26-000043.md) | [59.0](/filings/0001092699-26-000066.md) | [57.1](/filings/0001092699-26-000075.md) |
| Gross profit | $m | [95.9 d](/filings/0001092699-26-000012.md) | [98.1](/filings/0001092699-25-000038.md) | [102](/filings/0001092699-25-000049.md) | [112](/filings/0001092699-25-000064.md) | [115 d](/filings/0001092699-26-000012.md) | [125](/filings/0001092699-26-000043.md) | [128](/filings/0001092699-26-000066.md) | [132](/filings/0001092699-26-000075.md) | [136 d](/filings/0001092699-26-000012.md) | [133](/filings/0001092699-26-000043.md) | [139](/filings/0001092699-26-000066.md) | [141](/filings/0001092699-26-000075.md) |
| Research and development | $m | [14.2 d](/filings/0001092699-26-000012.md) | [16.0](/filings/0001092699-25-000038.md) | [14.4](/filings/0001092699-25-000049.md) | [15.3](/filings/0001092699-25-000064.md) | [17.1 d](/filings/0001092699-26-000012.md) | [17.4](/filings/0001092699-26-000043.md) | [17.3](/filings/0001092699-26-000066.md) | [17.3](/filings/0001092699-26-000075.md) | [16.7 d](/filings/0001092699-26-000012.md) | [17.9](/filings/0001092699-26-000043.md) | [17.0](/filings/0001092699-26-000066.md) | [16.5](/filings/0001092699-26-000075.md) |
| Operating income | $m | [22.9 d](/filings/0001092699-26-000012.md) | [15.4](/filings/0001092699-25-000038.md) | [23.2](/filings/0001092699-25-000049.md) | [25.6](/filings/0001092699-25-000064.md) | [24.7 d](/filings/0001092699-26-000012.md) | [26.0](/filings/0001092699-26-000043.md) | [26.5](/filings/0001092699-26-000066.md) | [31.2](/filings/0001092699-26-000075.md) | [34.7 d](/filings/0001092699-26-000012.md) | [24.6](/filings/0001092699-26-000043.md) | [8.4](/filings/0001092699-26-000066.md) | [39.9](/filings/0001092699-26-000075.md) |
| Interest expense | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [7.3 d](/filings/0001092699-26-000012.md) | [0.5](/filings/0001092699-25-000038.md) | [9.2](/filings/0001092699-25-000049.md) | [5.9](/filings/0001092699-25-000064.md) | [6.8 d](/filings/0001092699-26-000012.md) | [6.0](/filings/0001092699-26-000043.md) | [7.5](/filings/0001092699-26-000066.md) | [6.9](/filings/0001092699-26-000075.md) | [10.1 d](/filings/0001092699-26-000012.md) | [6.2](/filings/0001092699-26-000043.md) | [3.5](/filings/0001092699-26-000066.md) | [10.6](/filings/0001092699-26-000075.md) |
| Net income | $m | [19.0 d](/filings/0001092699-26-000012.md) | [18.0](/filings/0001092699-25-000038.md) | [18.0](/filings/0001092699-25-000049.md) | [23.5](/filings/0001092699-25-000064.md) | [17.6 d](/filings/0001092699-26-000012.md) | [22.2](/filings/0001092699-26-000043.md) | [19.7](/filings/0001092699-26-000066.md) | [25.6](/filings/0001092699-26-000075.md) | [25.8 d](/filings/0001092699-26-000012.md) | [19.7](/filings/0001092699-26-000043.md) | [6.9](/filings/0001092699-26-000066.md) | [30.7](/filings/0001092699-26-000075.md) |
| Diluted EPS | $ per share | not reported | [0.48](/filings/0001092699-25-000038.md) | [0.48](/filings/0001092699-25-000049.md) | [0.62](/filings/0001092699-25-000064.md) | not reported | [0.58](/filings/0001092699-26-000043.md) | [0.52](/filings/0001092699-26-000066.md) | [0.67](/filings/0001092699-26-000075.md) | not reported | [0.53](/filings/0001092699-26-000043.md) | [0.19](/filings/0001092699-26-000066.md) | [0.85](/filings/0001092699-26-000075.md) |
| Basic EPS | $ per share | not reported | [0.49](/filings/0001092699-25-000038.md) | [0.49](/filings/0001092699-25-000049.md) | [0.63](/filings/0001092699-25-000064.md) | not reported | [0.58](/filings/0001092699-26-000043.md) | [0.52](/filings/0001092699-26-000066.md) | [0.67](/filings/0001092699-26-000075.md) | not reported | [0.53](/filings/0001092699-26-000043.md) | [0.19](/filings/0001092699-26-000066.md) | [0.85](/filings/0001092699-26-000075.md) |

- Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
- Cost of revenue: us-gaap:CostOfRevenue
- Gross profit: us-gaap:GrossProfit
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: not reported
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [219](/filings/0001092699-25-000011.md) | [235](/filings/0001092699-24-000046.md) | [240](/filings/0001092699-24-000060.md) | [199](/filings/0001092699-24-000074.md) | [241](/filings/0001092699-26-000012.md) | [94.9](/filings/0001092699-25-000038.md) | [108](/filings/0001092699-25-000049.md) | [134](/filings/0001092699-25-000064.md) | [151](/filings/0001092699-26-000075.md) | [154](/filings/0001092699-26-000043.md) | [173](/filings/0001092699-26-000066.md) | [154](/filings/0001092699-26-000075.md) |
| Current assets | $m | [401](/filings/0001092699-25-000011.md) | [420](/filings/0001092699-24-000046.md) | [407](/filings/0001092699-24-000060.md) | [345](/filings/0001092699-24-000074.md) | [382](/filings/0001092699-26-000012.md) | [252](/filings/0001092699-25-000038.md) | [269](/filings/0001092699-25-000049.md) | [316](/filings/0001092699-25-000064.md) | [335](/filings/0001092699-26-000075.md) | [329](/filings/0001092699-26-000043.md) | [330](/filings/0001092699-26-000066.md) | [347](/filings/0001092699-26-000075.md) |
| Total assets | $m | [824](/filings/0001092699-25-000011.md) | [840](/filings/0001092699-24-000046.md) | [855](/filings/0001092699-24-000060.md) | [1,003](/filings/0001092699-24-000074.md) | [1,031](/filings/0001092699-26-000012.md) | [1,109](/filings/0001092699-25-000038.md) | [1,121](/filings/0001092699-25-000049.md) | [1,159](/filings/0001092699-25-000064.md) | [1,170](/filings/0001092699-26-000075.md) | [1,161](/filings/0001092699-26-000043.md) | [1,125](/filings/0001092699-26-000066.md) | [1,133](/filings/0001092699-26-000075.md) |
| Current liabilities | $m | [131](/filings/0001092699-25-000011.md) | [134](/filings/0001092699-24-000046.md) | [129](/filings/0001092699-24-000060.md) | [146](/filings/0001092699-24-000074.md) | [147](/filings/0001092699-26-000012.md) | [153](/filings/0001092699-25-000038.md) | [148](/filings/0001092699-25-000049.md) | [160](/filings/0001092699-25-000064.md) | [154](/filings/0001092699-26-000075.md) | [155](/filings/0001092699-26-000043.md) | [146](/filings/0001092699-26-000066.md) | [154](/filings/0001092699-26-000075.md) |
| Total liabilities | $m | [156](/filings/0001092699-25-000011.md) | [157](/filings/0001092699-24-000046.md) | [151](/filings/0001092699-24-000060.md) | [174](/filings/0001092699-24-000074.md) | [177](/filings/0001092699-26-000012.md) | [188](/filings/0001092699-25-000038.md) | [171](/filings/0001092699-25-000049.md) | [200](/filings/0001092699-25-000064.md) | [196](/filings/0001092699-26-000075.md) | [199](/filings/0001092699-26-000043.md) | [187](/filings/0001092699-26-000066.md) | [200](/filings/0001092699-26-000075.md) |
| Shareholders' equity | $m | [667](/filings/0001092699-26-000012.md) | [683](/filings/0001092699-25-000049.md) | [703](/filings/0001092699-25-000064.md) | [829](/filings/0001092699-25-000064.md) | [855](/filings/0001092699-26-000075.md) | [921](/filings/0001092699-26-000066.md) | [950](/filings/0001092699-26-000075.md) | [959](/filings/0001092699-26-000075.md) | [974](/filings/0001092699-26-000075.md) | [962](/filings/0001092699-26-000066.md) | [938](/filings/0001092699-26-000075.md) | [933](/filings/0001092699-26-000075.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [32.8 d](/filings/0001092699-26-000012.md) | [34.1](/filings/0001092699-25-000038.md) | [29.4 d](/filings/0001092699-25-000049.md) | [53.3 d](/filings/0001092699-25-000064.md) | [40.6 d](/filings/0001092699-26-000012.md) | [40.0](/filings/0001092699-26-000043.md) | [32.3 d](/filings/0001092699-26-000066.md) | [60.6 d](/filings/0001092699-26-000075.md) | [45.9 d](/filings/0001092699-26-000012.md) | [55.6](/filings/0001092699-26-000043.md) | [66.0 d](/filings/0001092699-26-000066.md) | [64.0 d](/filings/0001092699-26-000075.md) |
| Capital expenditure | $m | [4.3 d](/filings/0001092699-26-000012.md) | [3.5](/filings/0001092699-25-000038.md) | [5.1 d](/filings/0001092699-25-000049.md) | [5.2 d](/filings/0001092699-25-000064.md) | [6.2 d](/filings/0001092699-26-000012.md) | [6.2](/filings/0001092699-26-000043.md) | [6.7 d](/filings/0001092699-26-000066.md) | [6.1 d](/filings/0001092699-26-000075.md) | [7.7 d](/filings/0001092699-26-000012.md) | [7.1](/filings/0001092699-26-000043.md) | [8.6 d](/filings/0001092699-26-000066.md) | [5.5 d](/filings/0001092699-26-000075.md) |
| Share repurchases | $m | [0.0 d](/filings/0001092699-26-000012.md) | [16.5](/filings/0001092699-25-000038.md) | [20.9 d](/filings/0001092699-25-000049.md) | [0.1 d](/filings/0001092699-25-000064.md) | [0.0 d](/filings/0001092699-26-000012.md) | [40.0](/filings/0001092699-26-000043.md) | [19.6 d](/filings/0001092699-26-000066.md) | [30.0 d](/filings/0001092699-26-000075.md) | [24.7 d](/filings/0001092699-26-000012.md) | [47.1](/filings/0001092699-26-000043.md) | [51.2 d](/filings/0001092699-26-000066.md) | [48.8 d](/filings/0001092699-26-000075.md) |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | Q3 FY2026 (2026-09-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [37.2](/filings/0001092699-24-000046.md) | [37.4](/filings/0001092699-24-000060.md) | [37.6](/filings/0001092699-24-000074.md) | [37.7](/filings/0001092699-25-000038.md) | [37.7](/filings/0001092699-25-000049.md) | [38.0](/filings/0001092699-25-000064.md) | [38.2](/filings/0001092699-26-000043.md) | [38.1](/filings/0001092699-26-000066.md) | [38.0](/filings/0001092699-26-000075.md) | [37.4](/filings/0001092699-26-000043.md) | [36.6](/filings/0001092699-26-000066.md) | [36.2](/filings/0001092699-26-000075.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 35,440,926 at 2026-10-22, from the cover of the [10-Q filed 2026-10-29](/filings/0001092699-26-000075.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 29, 2026, 17:33 ET. No prices; not investment advice.